latest news releases from the newsroom
Infinity Pharmaceuticals, Inc.
Infinity and MedImmune Present Preliminary Phase 1 Data Demonstrating Biological Activity of IPI-504, A Novel Hsp90 Inhibitor, in Advanced Non-Small Cell Lung Cancer
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 25, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced preliminary results of an ongoing Phase 1/2 clinical trial of IPI-504, the companies' lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Seven of nine evaluable patients receiving IPI-504 achieved disease stabilization over at least one cycle of administration, and four of four evaluated patients who underwent positron emission tomography (PET) imaging exhibited a decrease in tumor metabolic activity in response to IPI-504 administration. The data were presented yesterday at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.
Zecotek Photonics Inc.
Zecotek's Patented LFS Scintillation Crystals Selected For Trials by the Paul Scherrer Institute, Switzerland
VANCOUVER, British Columbia, Oct. 25, 2007 (PRIME NEWSWIRE) -- Zecotek Medical Systems Inc. (TSX-V:ZMS) (Frankfurt:W1I) today announced the Paul Scherrer Institute based in Switzerland has purchased an order of Zecotek's patented Lutetium Fine Silicate (LFS) scintillation crystals for trials in its next-generation Positron Emission Tomography (PET) medical imaging program. The Paul Scherrer Institute PET program is focused on advancing improvements in sensitivity, spatial resolution and image quality in PET scanners, based on the understanding that advances in PET are driven largely by progress in instrumentation, in particular the performance of scintillation materials, photo-detectors and read-out electronics. Higher resolution PET scanners would also widen PET's application in brain function analysis and diagnosis.